These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 24749495)
1. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Ishida T; Kano Y; Mizukawa Y; Shiohara T Allergy; 2014 Jun; 69(6):798-805. PubMed ID: 24749495 [TBL] [Abstract][Full Text] [Related]
2. Saliva polymerase chain reaction assay for detection and follow-up of herpesvirus reactivation in patients with drug reaction with eosinophilia and systemic symptoms (DRESS). Descamps V; Avenel-Audran M; Valeyrie-Allanore L; Bensaid B; Barbaud A; Al Jawhari M; Ranger-Rogez S; JAMA Dermatol; 2013 May; 149(5):565-9. PubMed ID: 23426332 [TBL] [Abstract][Full Text] [Related]
3. Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Tohyama M; Hashimoto K; Oda F; Namba C; Sayama K J Dermatol; 2020 May; 47(5):476-482. PubMed ID: 32162382 [TBL] [Abstract][Full Text] [Related]
4. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Teraki Y; Shibuya M; Izaki S Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350 [TBL] [Abstract][Full Text] [Related]
5. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Seishima M; Yamanaka S; Fujisawa T; Tohyama M; Hashimoto K Br J Dermatol; 2006 Aug; 155(2):344-9. PubMed ID: 16882173 [TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms. Takehara A; Aoyama Y; Kurosawa M; Shirafuji Y; Umemura H; Kamiya K; Ushigome Y; Kano Y; Shiohara T; Iwatsuki K Br J Dermatol; 2016 Nov; 175(5):944-952. PubMed ID: 27087170 [TBL] [Abstract][Full Text] [Related]
7. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Kano Y; Hiraharas K; Sakuma K; Shiohara T Br J Dermatol; 2006 Aug; 155(2):301-6. PubMed ID: 16882166 [TBL] [Abstract][Full Text] [Related]
8. The role of human herpesvirus-6, Epstein–Barr virus and cytomegalovirus infections in the etiopathogenesis of different types of cutaneous drug reactions. Ozcan D; Seçkin D; Bilezikçi B; Arslan H Int J Dermatol; 2010 Nov; 49(11):1250-4. PubMed ID: 21038542 [TBL] [Abstract][Full Text] [Related]
9. The interferon-γ-induced protein 10/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms. Yang CW; Cho YT; Hsieh YC; Hsu SH; Chen KL; Chu CY Br J Dermatol; 2020 Nov; 183(5):909-919. PubMed ID: 32037509 [TBL] [Abstract][Full Text] [Related]
10. Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Mitsui Y; Shinkuma S; Nakamura-Nishimura Y; Ommori R; Ogawa K; Miyagawa F; Mori Y; Tohyama M; Asada H J Allergy Clin Immunol Pract; 2022 Feb; 10(2):558-565.e4. PubMed ID: 34757063 [TBL] [Abstract][Full Text] [Related]
11. Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions --a prospective comparative study. Chen YC; Chiang HH; Cho YT; Chang CY; Chen KL; Yang CW; Lee YH; Chu CY Allergy; 2015 May; 70(5):568-75. PubMed ID: 25727950 [TBL] [Abstract][Full Text] [Related]
12. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. Pavlos R; Mallal S; Ostrov D; Pompeu Y; Phillips E J Allergy Clin Immunol Pract; 2014; 2(1):21-33. PubMed ID: 24565765 [TBL] [Abstract][Full Text] [Related]
13. New aspects of drug-induced hypersensitivity syndrome. Tohyama M; Hashimoto K J Dermatol; 2011 Mar; 38(3):222-8. PubMed ID: 21342223 [TBL] [Abstract][Full Text] [Related]
14. Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. Ushigome Y; Mizukawa Y; Kimishima M; Yamazaki Y; Takahashi R; Kano Y; Shiohara T Clin Exp Allergy; 2018 Nov; 48(11):1453-1463. PubMed ID: 30112775 [TBL] [Abstract][Full Text] [Related]
15. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS). Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052 [TBL] [Abstract][Full Text] [Related]
16. Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome. Bohm KJ; Ciralsky JB; Harp JL; Bajaj S; Sippel KC Cornea; 2016 Jun; 35(6):888-91. PubMed ID: 27078005 [TBL] [Abstract][Full Text] [Related]
17. Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. Hama N; Abe R; Gibson A; Phillips EJ J Allergy Clin Immunol Pract; 2022 May; 10(5):1155-1167.e5. PubMed ID: 35176506 [TBL] [Abstract][Full Text] [Related]
18. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. Ushigome Y; Kano Y; Ishida T; Hirahara K; Shiohara T J Am Acad Dermatol; 2013 May; 68(5):721-8. PubMed ID: 23182063 [TBL] [Abstract][Full Text] [Related]
19. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Descamps V; Valance A; Edlinger C; Fillet AM; Grossin M; Lebrun-Vignes B; Belaich S; Crickx B Arch Dermatol; 2001 Mar; 137(3):301-4. PubMed ID: 11255328 [TBL] [Abstract][Full Text] [Related]
20. Predictive biomarkers for cytomegalovirus reactivation before and after immunosuppressive therapy: A single-institution retrospective long-term analysis of patients with drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic syndrome (DRESS). Mizukawa Y; Kimishima M; Aoyama Y; Shiohara T Int J Infect Dis; 2020 Nov; 100():239-246. PubMed ID: 32891735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]